Horizon Therapeutics (HZNP) Tops Q3 EPS by 22c

Horizon Therapeutics (NASDAQ: HZNP) reported Q3 EPS of $1.75, $0.22 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $977.52 million.

GUIDANCE:

Horizon Therapeutics raises FY2021 revenue to $3.16-3.21 billion, versus the consensus of $3.12 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance